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Introduction 
Multi-parametric magnetic resonance imaging (mpMRI) has emerged as a promising tool 
in the detection of clinically significant prostate cancer (csPCa).1-3 Limitations associated with 
the recognition of low-grade, low volume pathology can be considered a strength, as this allows 
for selection of patients with high-risk disease features, for which mpMRI exhibits remarkable 
specificity.2,4 In view of current criticisms by the United States Preventative Services Task Force 
(USPSTF) that prostate specific antigen (PSA) screening invites unnecessary intervention and 
treatment, the use of mpMRI as an adjunct to PSA creates opportunity to consider prostate 
biopsy primarily for those patients with highest suspicion for clinically significant disease.5,6  
Although level 1 evidence supports the ability of mpMRI to preferentially detect higher-
risk disease in patients with elevated PSA, results from existing trials are generated in highly 
idealized settings where comparison to cohorts evaluated with PSA alone involves the universal 
biopsy of all study patients for purposes of sensitivity and specificity analyses.1,6 In this respect, 
our understanding of the advantages of MRI to help guide biopsy decision in men with elevated 
PSA remains theoretical as no large-scale study to date evaluates its performance when 
integrated into a true clinical practice setting, where decisions for biopsy are not necessarily 
driven by defined protocols, but often based on personalized patient assessments.  
Herein, we investigated how the implementation of mpMRI and MR/US fusion-guided 
technology in two large academic and community urology practices within the United States 
influenced patterns of prostate biopsy and cancer detection in a large cohort of men who 
presented with elevated PSA. With the USPSTF guidelines highlighting the inherent weaknesses 
of PSA-based screening, we contend that use of mpMRI to triage patients with elevated PSA 
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would address these legitimate concerns in true clinical practice by decreasing biopsy rates, 
minimizing risks inherent in indiscriminate systematic prostate sampling, and enabling the 
preferential detection of csPCa when compared to men in whom biopsy decisions are guided by 
conventional clinical metrics centered around PSA.5,7 
 
Methods 
Following Institutional Review Board approval, data were retrospectively collected from 
patients (aged ≥18 years) referred for elevated PSA between June 2011 and November 2014 to 
two large independent academic-community practices in New York City and Long Island, NY 
(Smith Institute for Urology and Integrated Medical Professionals). The study population was 
divided into MRI and PSA-only groups based on whether patients underwent mpMRI of the 
prostate at any point during the specified accrual period. All patients were counseled on the use 
of mpMRI as a secondary test in the evaluation of elevated PSA. Reasons for MRI not being 
performed included lack of patient desire, medical contraindication to MRI, physician decision to 
defer imaging, or inability to obtain insurance approval for the MRI study (Supplementary Table 
1). Both cohorts were followed longitudinally until October 2016. Patients with prior prostate 
cancer (PCa) history, history of prostate MRI prior to initial visit during enrollment period, or 
<1-year follow-up were excluded. Patients in the PSA-only group who had negative biopsy 
during the accrual period and underwent subsequent mpMRI during follow-up comprised a 
distinct cohort and were not included in the primary analysis; this was done to enable a more 
representative description of biopsy practice and cancer-detection in a population evaluated 
purely based conventional clinical metrics without MRI imaging.  
Variables evaluated included age, race, family history of PCa, prior negative prostate 
biopsy, digital rectal exam (DRE), baseline PSA, and prostate volume. Subjects undergoing MRI 
were stratified into two groups (positive or negative) based on the presence of suspicion lesions. 
Suspicious findings were defined based on a 5-point Likert scale as any lesions on MRI with 
Simplified Qualitative System (SQS) score ranging between 1 and 5, with a SQS score of ≤2 
corresponding to a negative MRI and an SQS score between 3 and 5 corresponding to a positive 
MRI and prompting fusion biopsy.8 The SQS scoring system has been previously described and 
was utilized as implementation of our institutional MRI program predated publication of the PI-
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RADS classification. Nevertheless, we have demonstrated similar overall risk stratification of 
MRI lesions based on SQS and PI-RADS V2 scoring systems.8  
 Patients were evaluated for use of post-MRI or post-PSA prostate biopsy in MRI and 
PSA-only cohorts, respectively, as well as biopsy pathology when applicable. Individuals with 
positive MRI were offered MRI/Transrectal ultrasound (TRUS) fusion-guided biopsy of 
suspicious lesions in addition to standard 12-core biopsy, performed during the same setting. 
Fusion biopsy was performed using the UroNav MRI/TRUS (end-fire iU22 ultrasound, Philips 
Healthcare, Netherlands) fusion guided prostate biopsy system (Invivo, Gainesville, FL). Two 
biopsy cores were obtained from each lesion; one in the axial and the other in the sagittal plane. 
After targeted biopsy was performed of the suspicious lesion(s), the UroNav workstation where 
the MRI was processed was turned off and a standard 12-core systematic TRUS-guided prostate 
biopsy was subsequently performed.    
Clinically significant PCa was defined as any Gleason score ≥7 on fusion or standard 12-
core TRUS biopsies, Gleason 6 with a lesion volume >0.5 cm3 volume on MRI, or Gleason 6 
with >2 cores positive and/or >50% of any core involved with cancer on biopsy per Epstein’s 
criteria.9 
Treating providers were the same for patients in both study groups. Biopsy was 
performed based on aggregate analysis of MRI findings (in the MRI cohort) and clinical 
variables including PSA, DRE, prior history of biopsy, race, and family history as well as patient 
desire. A 3-Tesla Verio® MRI (Siemens, Germany)  was performed using a 16-channel cardiac 
coil (Sense, Invivo®) and an endorectal coil (BPX-30, Medrad®, Pittsburgh, PA) filled with 
PFC-770 (3M®, St. Paul, MN).8 Sequences obtained included tri-planar T2-weighted imaging, 
axial diffusion-weighted imaging (b values 0, 50, 500, 1000, 1500, and 2000) with apparent 
diffusion coefficient mapping (b-values 0, 50, 500, 1000, 1500), and dynamic contrast-enhanced 
imaging. All mpMRI were read prospectively by experienced genitourinary radiologists and 
scored with a five-point Likert scale (SQS score) with sequence specific information that could 
be used to calculate other scoring systems that may arise (PI-RADSv1).8 Patients with a negative 
MRI who did not undergo biopsy were followed with PSA and/or interval imaging. 
Descriptive statistics are presented as counts and percentages for categorical variables 
and as means and standard deviations for continuous variables. The association of patient and 
disease characteristics by study group (i.e. MRI vs. PSA-only) was analyzed with Student’s t-test 
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for continuous data and chi-square test for categorical variables in univariable analysis. Primary 
outcomes included rate of prostate biopsy in MRI versus PSA-only groups as well as overall PCa 
detection among all-comers and those who had a post-MRI/PSA prostate biopsy. Secondary 
outcomes included presence of Gleason score 6, 7, and 8-10 cancers as well as csPCa among 
biopsied patients in the MRI versus PSA-only groups. Multivariable analysis of PCa detection 
variables was conducted with multinomial logistic regressions adjusting for the covariates age, 
race, family history of PCa, DRE, history of previous negative biopsy, and baseline PSA. All 
analyses were two-tailed and performed using Stata 14.2 (College Station, TX). A P<0.05 was 
considered statistically significant. 
 
Results 
Between June 2011 and November 2014, 2073 patients without history of PCa presented 
to both urology practices for evaluation of elevated PSA. 167 patients evaluated with PSA only 
during the accrual period underwent subsequent mpMRI during follow-up and were not included 
in the analysis. 42 patients who had an MRI of the prostate prior to accrual and 56 patients with 
follow-up <1 year were excluded. The final study cohort consisted of 1020 patients and 788 
patients in MRI and PSA-only arms, respectively (Supplementary Figure). Patient 
demographics and clinical characteristics are delineated in Table 1. Prior negative biopsy (59.9% 
vs. 32.6%, P<0.001) was significantly more frequent among those undergoing MRI. No 
differences in baseline PSA, DRE, family history and race were appreciated between cohorts. Of 
the 1020 patients undergoing MRI, 452 (44.3%) patients had a positive MRI. The distribution of 
suspicion scores for observed lesions is presented in Supplementary Table 2. 
Over a median follow-up of 3.1 years, a total 465 (45.6%) and 442 (56.1%) patients 
underwent biopsy in the MRI and in PSA-only groups, respectively, corresponding to an 18.7% 
decrease in the proportion of patients undergoing biopsy in the MRI group (P<0.001, Table 2). 
Biopsy was performed in 378 (83.6%) patients with positive MRI versus 87 (15.3%) with 
negative MRI. Median follow-up among patients with a negative MRI who did not undergo 
biopsy was 3.6 years. Repeat mpMRI was performed in 35 (7.3%) patients, with the study 
having remained negative in all patients. One patient had undergone biopsy from this cohort and 
was negative for PCa. Median follow-up for patients in the PSA-only group who did not undergo 
biopsy or had negative biopsy was 3.4 years 
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Among biopsied patients, overall PCa (56.8% vs. 40.7%, P<0.001) and csPCa detection 
(47.3% vs. 31.0%, p<0.001) were significantly higher in the MRI versus PSA-only group, 
corresponding to increased detection of GS 7 lesions (52.3% vs. 40.6%, P=0.018) and decreased 
detection of GS 6 disease (27.7% vs. 40%, P=0.018, Table 2). In multivariable analysis, the odds 
of overall PCa (OR=1.74, 95%CI=1.29-2.35, P<0.001) and csPCa detection (OR=2.04, 
95%CI=1.48-2.80, P<0.001) were significantly higher in the MRI compared to PSA-only group 
(Table 3). 
Biopsy rates and pathologic findings stratified by MRI result and SQS scores are 
presented in Supplementary Table 2. Incidence of csPCa within lesions of SQS score 3, 4, and 
5 was 27.5%, 70.9%, and 98.5%, respectively. Among the 87 patients with negative MRI who 
underwent biopsy, cancer was detected in 15 (17.2%) cases, with 8 (9.2%) having qualified as 
clinically significant disease. 
324 (85.7%) of 378 patients with a positive MRI underwent combined fusion with 12-
core systematic TRUS biopsy (Table 4 and Supplementary Table 3). Overall cancer detection 
rate in this group was 65.7%, including 54.9% for fusion biopsies and 54.3% for 12-core 
systematic biopsies. Detection of csPCa, however, was significantly higher on targeted fusion 
biopsy than on 12-core systematic TRUS biopsy (50.3% vs 41.4%, p=0.022, Table 4), which 
corresponded to increased detection of GS 7 lesions (60.5% vs. 47.7%, P=0.009). Of the 14 
clinically significant tumors missed on fusion biopsy, seven were GS 6 tumors and seven were 
GS 7 tumors.  
 
Discussion 
Improved understanding of the biologic heterogeneity of PCa has unveiled the gross 
over-detection and often unnecessary treatment of clinically insignificant cancers through widely 
utilized PSA-based screening practices.5,7 Consensus statements issued by the USPSTF arguing 
against the universal use of PSA would theoretically diminish morbidity related to diagnosis of 
low-risk PCa, but also leave vulnerable a population of patients with higher-risk pathologies 
shown to benefit from primary intervention.5,7,10-14 This dilemma highlights the need for a more 
refined approach to the management of patients with elevated PSA that selectively identifies 
patients with clinically significant disease.  
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Our study results offer a real-world interpretation of how integration of MRI technology 
in the triage of patients with elevated PSA influences patterns of prostate biopsy and cancer 
detection compared to PSA alone.  We show in the clinical practice setting that utilization of 
MRI as a risk-assessment tool significantly reduces the use of prostate biopsy when compared to 
clinical decision-making based on PSA alone. At 3.1-year follow-up, an 18.7% reduction in 
biopsy rate among men evaluated with MRI was observed in the context of biopsy being 
performed in only 15.3% of men with negative MRI compared to 83.6% of men with positive 
MRI. Moreover, despite the reduction in biopsy rate, PCa detection increased by 39.4% in the 
MRI cohort, which corresponded with a 52.6% increase in detection of clinically significant 
pathology. Benefit derived from MRI was seen to extend beyond the identification of men with a 
positive study, but also involved the ability to perform targeted biopsy of suspicious lesions as 
incidence of csPCa was appreciably higher among patients receiving combined fusion with 
systematic 12-core TRUS biopsy than in patients with positive MRI who only underwent non-
targeted 12-core TRUS biopsy. 
Several studies lend support to our findings, albeit in the context of highly idealized trial 
scenarios. In a pilot study nested within the Goteborg randomized screening trial, use of targeted 
biopsy alone in 124 men with a suspicious lesion on pre-biopsy MRI would reduce biopsy rates 
by at least 33% while leading to an 48% increase in detection of csPCa when compared to 
systematic biopsy based on elevated PSA value alone.15 Similarly, in a prospective assessment of 
MRI use in the setting of elevated PSA, the PROMIS trial presented two hypothetical models for 
patient evaluation: one based on standard practice of TRUS biopsy in men with elevated PSA, 
and another utilizing MRI as a triage tool, reserving biopsy for men with suspicious imaging 
lesions. Comparison of both pathways revealed a significantly higher positive predictive value 
for the MRI-based approach, as the incidence of csPCa in standard TRUS biopsy and MRI 
biopsy cohorts was 19% and 51%, respectively.1 Most recently, Kasivisvanathan et al 
randomized 500 patients at risk of PCa to TRUS biopsy or MRI/ultrasound-guided fusion biopsy 
and determined that using MRI prior to biopsy was superior to standard TRUS biopsy with 
regards to increased detection of csPCa and reduced detection of clinically-insignificant disease.6  
Our study places the findings of the PROMIS and PRECISION trials into more practical 
context, illustrating in a contemporary practice setting how implementation of MRI into the 
triage algorithm for elevated PSA would indeed facilitate preferential identification of patients 
Au
th
or
 M
an
us
cr
ip
t
 This article is protected by copyright. All rights reserved 
with aggressive disease while mitigating over-diagnosis of insignificant pathology. Fundamental 
assumptions of both the PROMIS and PRECISION trials predicating the superiority of an MRI-
based risk assessment are that firstly, all patients presenting with elevated PSA would be 
candidates for MRI and that secondly, TRUS biopsy would be performed in all patients with 
elevated PSA, both of which are not representative of true clinical practice within the United 
States; in fact, among 788 patients in our study’s PSA-only group, only 56% went on to receive 
biopsy at a median 3.1 year follow-up. Nevertheless, despite the selective use of biopsy even in 
the PSA-only cohort, we still observed a significantly higher positive predictive value for cancer 
detection with the MRI-based approach, with csPCa detection having increased over 50% when 
compared to biopsy based on PSA alone. Also notable is the higher detection rate for csPCa in 
the MRI cohort despite greater incidence of prior negative biopsy, further supporting the 
sensitivity of MRI for aggressive disease phenotypes compared with PSA-driven systematic 
biopsy. 
The benefit we observed to performing targeted biopsy of suspicious lesions is consistent 
with what is reported in the contemporary literature.2,16,17 A systematic review evaluating the role 
of MRI with and without fusion technology demonstrated that while overall PCa diagnosis rates 
were similar between targeted biopsy and non-targeted 12-core TRUS biopsy, use of targeted 
biopsy significantly increased detection of aggressive subtypes.16 Similarly, addition of standard 
TRUS biopsy to targeted biopsy in patients with positive MRI was shown to be of limited utility 
by Siddiqui et al in a landmark prospective trial evaluating MR-fusion biopsy in 1003 patients 
with clinical suspicion for PCa. Although the combination of 12-core TRUS biopsy and targeted 
biopsy increased diagnosis of PCa by 10% in their study cohort, less than half would qualify as 
clinically significant with only 3% representing intermediate or high-risk disease.2 
A diagnostic platform integrating MRI as a secondary test in men with elevated PSA 
would be premised on omission of biopsy in the absence of suspicious imaging lesions, a 
practice which raises concern for the missed detection of clinically significant disease in patients 
with elevated PSA but negative MRI. Previous attempts to discern the negative predictive value 
(NPV) of MRI are limited by selection biases inherent in the study of radical prostatectomy 
cohorts, largely skewing disease detection rates. A more accurate assessment of MRI sensitivity 
for csPCa is provided by the PROMIS trial, as transperineal mapping biopsy of men with 
elevated PSA without a diagnosis of PCa represents a more balanced pathologic reference 
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standard. Using Gleason score ≥4+3 as a primary definition for csPCa, Ahmed et al observed 
that 89% of men with negative MRI had absent or indolent pathology on transperineal biopsy, 
translating to a NPV significantly higher than that seen after standard 12-core TRUS biopsy 
when performed for elevated PSA.1 Even when considering a more inclusive definition for 
csPCa (GS≥3+4 or cancer core length ≥4mm), which is more in line with our study criteria, the 
NPV of MRI (72%) remained significantly greater than 12-core TRUS biopsy (65%), indicating 
that while MRI is not perfect at excluding the presence of clinically significant disease, it does 
demonstrate incremental benefit over the current standard practice of non-targeted systematic 
TRUS biopsy.1  
Although our series may underestimate the risk for missed detection of csPCa in the MRI 
cohort given that biopsy was not performed in all patients with negative MRI, there are several 
factors that allow us to infer a relatively favorable NPV from the current literature.1,17 All 
patients in our series received high-quality imaging using a 3-Tesla magnet with an endorectal 
coil, meeting the standards of the American College of Radiology as outlined in the PI-RADS 
V2 module.18 Furthermore, biopsy was only performed by experienced providers well beyond 
their initial learning curve. This is in contrast to the PROMIS and PRECISION trials, in which a 
favorable negative predictive value and a high level of confidence in a negative MRI result was 
achieved despite use of 1.5-Tesla magnet without endorectal coil and biopsy being performed by 
providers with varying level of experience.1,6 Thus, the high- quality of MRI performed in the 
present study would lead us to believe that our rate of missed csPCa in negative MRI patients is 
not significantly different than what is established in the current literature. Nevertheless, as 
biopsy was not performed in all patients with negative MRI, broader conclusions regarding the 
NPV of MRI in men with elevated PSA cannot be drawn from this study. 
Several limitations of our study should be noted. Biopsy in both study cohorts was 
performed at the discretion of individual practitioners after evaluation of imaging and patient-
specific clinical characteristics rather than based on set criteria, potentially contributing to 
differences in biopsy rates and PCa detection. However, our study objective was to capture this 
variability that often exists in true clinical practice and demonstrate the utility of mpMRI as a 
risk-assessment tool within this framework. Reasons for MRI having not been performed 
were multifactorial and included lack of insurance approval as well as patient refusal. 
Inability to obtain insurance approval for MRI may have been a reflection of underlying 
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socioeconomic differences between the PSA-only and MRI groups, which may have in turn 
influenced observed differences in biopsy and cancer detection rates between groups. 
Similarly, patients who refused MRI may have done so because of an inherent inclination 
to proceed with biopsy in the setting of elevated PSA; this may have contributed to 
increased biopsy rates in the PSA-only group. A higher prior negative biopsy rate was 
observed in the MRI arm, which is not entirely unexpected given its current use primarily in this 
setting. Although this may have influenced biopsy practice patterns, higher cancer detection rates 
in this cohort speaks to a strength of MRI as a tool to capture disease which may have otherwise 
been missed using conventional PSA-based screening. Furthermore, our study offers real-world 
perspective on the feasibility of integrating MRI technology into the contemporary clinical 
practice setting, where the universal use of MRI in the evaluation of patients with elevated PSA 
is currently not standard practice.  
The negative stigma associated with PSA screening based on the USPSTF 
recommendations may have also influenced the decision to pursue biopsy among patients 
presenting with elevated PSA and explain in part differences between study groups. 
Nevertheless, any impact of the USPSTF guidelines on subsequent decision for biopsy 
would have likely been distributed equally among PSA-only and MRI groups given the 
temporal overlap of both cohorts as well as the focus of these recommendations having 
been on the role of PSA screening rather than the decision for biopsy among those with 
elevated PSA. Furthermore, several factors mitigate the impact of this policy shift on 
observed differences between groups, including study of the same providers prior to and 
after 2012 as well as the lack of corresponding changes in PSA-testing and biopsy 
guidelines set forth by the American Urological Association or American Cancer Society. 
The use of endorectal coil in our series may not be representative of current practice given 
improvements in mpMRI technology. However, use of endorectal coil in our series was based on 
limitations in the amount of signal needed to obtain high quality prostate imaging in the early 
phase of our MRI program.19  The limited follow-up of our study cohort is a limitation, 
particularly with respect to the consequences of missing csPCa in patients with negative MRI. 
All patients in our study, however, would reenter a PSA screening protocol and undergo repeat 
evaluation in the context of concerning PSA change with repeat MRI or standardized biopsy. 
This practice may mitigate, but not entirely eliminate, the risks of missed detection of csPCa in 
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patients for whom initial biopsy was deferred due to a negative MRI result. Lastly, patients were 
from two independent but regionally-confined academic-community practices. Studies from 
centers across the country are needed to confirm generalizability. 
In conclusion, with the growing body of level 1 evidence supporting mpMRI in the 
assessment of a man’s risk of PCa,1,2,6 we demonstrate that when implemented in clinical 
practice, the use of mpMRI to triage patients with elevated PSA does indeed increase detection 
of csPCa in the context of reduced number of prostate biopsies. Although these improvements 
support a possible paradigm shift in the evaluation of patients with elevated PSA, we also 
recognize that the full impact of MRI to guide biopsy decision is not currently understood and 
will likely require a decade of follow-up to understand its clinical relevance. As such, our study 
results support the notion that in the short-term, use of MRI as a triage tool in men with elevated 
PSA offers opportunity to better diagnose and risk-stratify PCa than the status quo. 
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Taďle 1: Baseline partiĐipants’ ĐharaĐteristiĐs ďy era 
Variable 
All comers PSA-only program MRI program 
P
*
 
N % N % N % 
N 1808 100% 788 43.6% 1020 56.4% - 
Race     
  
0.17 
African American 203 11.2% 92 11.7% 111 10.9% 
 
Caucasian 1111 61.5% 477 60.6% 634 62.2% 
 
Asian 169 9.4% 86 10.9% 83 8.1% 
 
Hispanic 44 2.4% 16 2.0% 28 2.7% 
 
Other/unknown 281 15.5% 117 14.8% 164 16.1% 
 
Family history    
   
0.27 
No 1452 80.3% 642 81.5% 810 79.4% 
 
Yes 356 19.7% 146 18.5% 210 20.6% 
 
DRE    
   
0.943 
Normal 1628 90.0% 710 90.1% 918 90.0% 
 
Abnormal 180 10.0% 78 9.9% 102 10.0% 
 
Prior negative biopsy     
  
<0.001 
No 940 52.0% 531 67.4% 409 40.1% 
 
Yes 868 48.0% 257 32.6% 611 59.9% 
 
        
Variable Mean SD Mean SD Mean SD P
†
 
Age (years) 63.9 7.6 62.7 7.4 64.8 7.7 <0.001 
Baseline PSA (ng/dL) 7.6 14.9 7.2 21.1 8.0 7.2 0.268 
Prostate volume (cc) 55.9 32.8 55.3 29.2 56.6 30.1 0.13 
        
DRE: digital rectum examination, MRI: magnetic resonance imaging, PSA: prostate-specific antigen, SD: 
standard deviation 
*
Chi-square test 
†
Student t test 
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Table 2: Prostate cancer characteristics by group 
Variable 
All comers PSA-only program MRI program 
P
*
 
N % N % N % 
All cancers 
(biopsied patients) 
      <0.001 
No 463 51.0% 262 59.3% 201 43.2%  
Yes 444 49.0% 180 40.7% 264 56.8%  
Clinically significant
1 
(biopsied patients) 
      <0.001 
No 554 61.1% 305 69.0% 249 53.5%  
Yes 353 38.9% 137 31.0% 216 46.5%  
Gleason score 
(biopsied patients) 
    
  
0.021 
2-6 146 32.9% 72 40.0% 74 28.0% 
 
7 211 47.5% 73 40.6% 138 52.3% 
 
8-10 87 19.6% 35 19.4% 52 19.7% 
 
        
MRI: magnetic resonance imaging, PSA: prostate-specific antigen 
*
Chi-square test 
1
 Gleason score ≥ 7, Gleason score 6 with MRI-visible lesion volume ≥ 0.5cc, or Gleason score 6 with 
>2 positive cores and/or >50% involvement of any core 
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Table 3: Multivariable analysis of prostate cancer detection comparing MRI program to PSA-only 
program 
Prostate cancer 
Univariable Multivariable
ΐ
 
OR 95% CI P
*
 OR 95% CI P
*
 
All cancers (biopsied patients) 1.84 1.41-2.40 <0.001 1.74 1.29-2.35 <0.001 
Clinically significant
1
 (biopsied patients) 2.00 1.52-2.62 <0.001 2.04 1.48-2.80 <0.001 
       
Prostate cancer
ΐ
 RRR 95% CI P
Ώ
 RRR 95% CI P
Ώ
 
Gleason score (biopsied patients) 2-6 ref. - - ref. - - 
 7 1.86 1.21-2.87 0.005 1.90 1.16-3.11 0.010 
 8-10 1.47 0.86-2.51 0.164 1.58 0.83-2.99 0.164 
OR: odds ratio, RRR: relative risk ratio 
*
Logistic regression 
†
Multinomial logistic regression 
ΐ
Analyses adjusted for: age, race, family history of prostate cancer, digital rectal exam, history of 
previous negative prostate biopsy and baseline prostate-specific antigen. 
1
 Gleason score ≥ 7, Gleason score 6 with MRI-visible lesion volume ≥ 0.5cc, or Gleason score 6 with 
>2 positive cores and/or >50% involvement of any core 
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Table 4: Prostate cancer characteristics by biopsy type in patients who underwent MRI-guided fusion biopsy 
 
Combined fusion and 12-core (+ MRI) P* 
All Fusion Target 12-core 
N % N % N % 
N 324 - 324 - 324 -   
All cancers       0.875 
No 111 34.3% 146 45.1% 148 45.7%   
Yes 213 65.7% 178 54.9% 176 54.3%   
Clinically significant
1
       0.022 
No 147 45.4% 161 49.7% 190 58.6%   
Yes 177 54.6% 163 50.3% 134 41.4%   
Gleason score       0.009 
2-6 52 24.4% 36 20.3% 61 34.7%   
7 118 55.4% 107 60.5% 84 47.7%   
8-10 43 20.2% 34 19.2% 31 17.6%   
MRI: magnetic resonance imaging 
*
Chi-square test 
1Gleason score ≥ 7, Gleason score 6 with MRI-visible lesion volume ≥ 0.5cc, or Gleason score 6 with >2 positive 
cores and/or >50% involvement of any core 
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